Reduction of filaritic lymphoedema and elephantiasis by 5,6 benzo-alpha-pyrone (coumarin), and the effects of diethylcarbamazine (DEC).
Identifieur interne : 00B479 ( Ncbi/Merge ); précédent : 00B478; suivant : 00B480Reduction of filaritic lymphoedema and elephantiasis by 5,6 benzo-alpha-pyrone (coumarin), and the effects of diethylcarbamazine (DEC).
Auteurs : J R Casley-Smith [Australie] ; S. Jamal ; J. Casley-SmithSource :
- Annals of tropical medicine and parasitology [ 0003-4983 ] ; 1993.
Descripteurs français
- KwdFr :
- MESH :
- traitement médicamenteux : Filariose lymphatique, Lymphoedème.
- usage thérapeutique : Coumarines, Diéthylcarbamazine.
- Adulte, Adulte d'âge moyen, Association de médicaments, Femelle, Humains, Mâle, Méthode en double aveugle, Sujet âgé.
English descriptors
- KwdEn :
- MESH :
- chemical , therapeutic use : Coumarins, Diethylcarbamazine.
- drug therapy : Elephantiasis, Filarial, Lymphedema.
- Adult, Aged, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Male, Middle Aged.
Abstract
Chronic filaritic lymphoedema and elephantiasis, in India, were treated orally with 5,6 benzo-alpha-pyrone (56 BaP; 1,2 benzo-alpha-pyrone; coumarin) in a double-blind, randomized, matched-group trial. Each group finally contained 40-55 patients. Patients were observed for about 2 years (ranging from 6 to 45 months, with 75% completing the 2 years). The 56 BaP slowly, but very significantly (P < 0.0001), reduced all grades of lymphoedema and elephantiasis. Two thirds of the oedema was lost by grade 2 over 2 years. Grades 3 to 5 were reduced by a fifty over that time. The greater the initial oedema, the greater was its rate of resolution. A slowly worsening condition thus became a slowly improving one. Slowness has its advantages: compression stockings, that are impractical in hot, wet or dirty conditions, are not necessary. The slowly remodelling fibrous tissue, while lessening in amount, is still able to hold the tissues together. The 56 BaP considerably improved many symptoms and complications, particularly bursting-pains, inflammation and ulcers. It is cheap and of very low toxicity. Diethylcarbamazine (DEC) was studied with and without 56 BaP. DEC alone gave some reduction of the oedema, but this was much smaller than that with 56 BaP. It considerably worsened the reductions by 56 BaP, while 56 Bap slightly improved those by DEC and reduced the fever caused by DEC. Together, they reduced feelings of swelling and bursting-pain, fungal infections, lymphangitis and lymphadenitis more than when used alone.
PubMed: 8257235
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 005732
- to stream PubMed, to step Curation: 005732
- to stream PubMed, to step Checkpoint: 005732
Links to Exploration step
pubmed:8257235Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Reduction of filaritic lymphoedema and elephantiasis by 5,6 benzo-alpha-pyrone (coumarin), and the effects of diethylcarbamazine (DEC).</title><author><name sortKey="Casley Smith, J R" sort="Casley Smith, J R" uniqKey="Casley Smith J" first="J R" last="Casley-Smith">J R Casley-Smith</name><affiliation wicri:level="1"><nlm:affiliation>Henry Thomas Laboratory, University of Adelaide, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Henry Thomas Laboratory, University of Adelaide</wicri:regionArea><wicri:noRegion>University of Adelaide</wicri:noRegion></affiliation></author><author><name sortKey="Jamal, S" sort="Jamal, S" uniqKey="Jamal S" first="S" last="Jamal">S. Jamal</name></author><author><name sortKey="Casley Smith, J" sort="Casley Smith, J" uniqKey="Casley Smith J" first="J" last="Casley-Smith">J. Casley-Smith</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1993">1993</date><idno type="RBID">pubmed:8257235</idno><idno type="pmid">8257235</idno><idno type="wicri:Area/PubMed/Corpus">005732</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">005732</idno><idno type="wicri:Area/PubMed/Curation">005732</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">005732</idno><idno type="wicri:Area/PubMed/Checkpoint">005732</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">005732</idno><idno type="wicri:Area/Ncbi/Merge">00B479</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Reduction of filaritic lymphoedema and elephantiasis by 5,6 benzo-alpha-pyrone (coumarin), and the effects of diethylcarbamazine (DEC).</title><author><name sortKey="Casley Smith, J R" sort="Casley Smith, J R" uniqKey="Casley Smith J" first="J R" last="Casley-Smith">J R Casley-Smith</name><affiliation wicri:level="1"><nlm:affiliation>Henry Thomas Laboratory, University of Adelaide, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Henry Thomas Laboratory, University of Adelaide</wicri:regionArea><wicri:noRegion>University of Adelaide</wicri:noRegion></affiliation></author><author><name sortKey="Jamal, S" sort="Jamal, S" uniqKey="Jamal S" first="S" last="Jamal">S. Jamal</name></author><author><name sortKey="Casley Smith, J" sort="Casley Smith, J" uniqKey="Casley Smith J" first="J" last="Casley-Smith">J. Casley-Smith</name></author></analytic><series><title level="j">Annals of tropical medicine and parasitology</title><idno type="ISSN">0003-4983</idno><imprint><date when="1993" type="published">1993</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Coumarins (therapeutic use)</term><term>Diethylcarbamazine (therapeutic use)</term><term>Double-Blind Method</term><term>Drug Therapy, Combination</term><term>Elephantiasis, Filarial (drug therapy)</term><term>Female</term><term>Humans</term><term>Lymphedema (drug therapy)</term><term>Male</term><term>Middle Aged</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Association de médicaments</term><term>Coumarines (usage thérapeutique)</term><term>Diéthylcarbamazine (usage thérapeutique)</term><term>Femelle</term><term>Filariose lymphatique (traitement médicamenteux)</term><term>Humains</term><term>Lymphoedème (traitement médicamenteux)</term><term>Mâle</term><term>Méthode en double aveugle</term><term>Sujet âgé</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Coumarins</term><term>Diethylcarbamazine</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Elephantiasis, Filarial</term><term>Lymphedema</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Filariose lymphatique</term><term>Lymphoedème</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Coumarines</term><term>Diéthylcarbamazine</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Double-Blind Method</term><term>Drug Therapy, Combination</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Association de médicaments</term><term>Femelle</term><term>Humains</term><term>Mâle</term><term>Méthode en double aveugle</term><term>Sujet âgé</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Chronic filaritic lymphoedema and elephantiasis, in India, were treated orally with 5,6 benzo-alpha-pyrone (56 BaP; 1,2 benzo-alpha-pyrone; coumarin) in a double-blind, randomized, matched-group trial. Each group finally contained 40-55 patients. Patients were observed for about 2 years (ranging from 6 to 45 months, with 75% completing the 2 years). The 56 BaP slowly, but very significantly (P < 0.0001), reduced all grades of lymphoedema and elephantiasis. Two thirds of the oedema was lost by grade 2 over 2 years. Grades 3 to 5 were reduced by a fifty over that time. The greater the initial oedema, the greater was its rate of resolution. A slowly worsening condition thus became a slowly improving one. Slowness has its advantages: compression stockings, that are impractical in hot, wet or dirty conditions, are not necessary. The slowly remodelling fibrous tissue, while lessening in amount, is still able to hold the tissues together. The 56 BaP considerably improved many symptoms and complications, particularly bursting-pains, inflammation and ulcers. It is cheap and of very low toxicity. Diethylcarbamazine (DEC) was studied with and without 56 BaP. DEC alone gave some reduction of the oedema, but this was much smaller than that with 56 BaP. It considerably worsened the reductions by 56 BaP, while 56 Bap slightly improved those by DEC and reduced the fever caused by DEC. Together, they reduced feelings of swelling and bursting-pain, fungal infections, lymphangitis and lymphadenitis more than when used alone.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">8257235</PMID><DateCreated><Year>1994</Year><Month>01</Month><Day>10</Day></DateCreated><DateCompleted><Year>1994</Year><Month>01</Month><Day>10</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0003-4983</ISSN><JournalIssue CitedMedium="Print"><Volume>87</Volume><Issue>3</Issue><PubDate><Year>1993</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Annals of tropical medicine and parasitology</Title><ISOAbbreviation>Ann Trop Med Parasitol</ISOAbbreviation></Journal><ArticleTitle>Reduction of filaritic lymphoedema and elephantiasis by 5,6 benzo-alpha-pyrone (coumarin), and the effects of diethylcarbamazine (DEC).</ArticleTitle><Pagination><MedlinePgn>247-58</MedlinePgn></Pagination><Abstract><AbstractText>Chronic filaritic lymphoedema and elephantiasis, in India, were treated orally with 5,6 benzo-alpha-pyrone (56 BaP; 1,2 benzo-alpha-pyrone; coumarin) in a double-blind, randomized, matched-group trial. Each group finally contained 40-55 patients. Patients were observed for about 2 years (ranging from 6 to 45 months, with 75% completing the 2 years). The 56 BaP slowly, but very significantly (P < 0.0001), reduced all grades of lymphoedema and elephantiasis. Two thirds of the oedema was lost by grade 2 over 2 years. Grades 3 to 5 were reduced by a fifty over that time. The greater the initial oedema, the greater was its rate of resolution. A slowly worsening condition thus became a slowly improving one. Slowness has its advantages: compression stockings, that are impractical in hot, wet or dirty conditions, are not necessary. The slowly remodelling fibrous tissue, while lessening in amount, is still able to hold the tissues together. The 56 BaP considerably improved many symptoms and complications, particularly bursting-pains, inflammation and ulcers. It is cheap and of very low toxicity. Diethylcarbamazine (DEC) was studied with and without 56 BaP. DEC alone gave some reduction of the oedema, but this was much smaller than that with 56 BaP. It considerably worsened the reductions by 56 BaP, while 56 Bap slightly improved those by DEC and reduced the fever caused by DEC. Together, they reduced feelings of swelling and bursting-pain, fungal infections, lymphangitis and lymphadenitis more than when used alone.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Casley-Smith</LastName><ForeName>J R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Henry Thomas Laboratory, University of Adelaide, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jamal</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Casley-Smith</LastName><ForeName>J</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Ann Trop Med Parasitol</MedlineTA><NlmUniqueID>2985178R</NlmUniqueID><ISSNLinking>0003-4983</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003374">Coumarins</NameOfSubstance></Chemical><Chemical><RegistryNumber>A4VZ22K1WT</RegistryNumber><NameOfSubstance UI="C030123">coumarin</NameOfSubstance></Chemical><Chemical><RegistryNumber>V867Q8X3ZD</RegistryNumber><NameOfSubstance UI="D004049">Diethylcarbamazine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003374" MajorTopicYN="N">Coumarins</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004049" MajorTopicYN="N">Diethylcarbamazine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004605" MajorTopicYN="N">Elephantiasis, Filarial</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008209" MajorTopicYN="N">Lymphedema</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1993</Year><Month>6</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1993</Year><Month>6</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1993</Year><Month>6</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">8257235</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Australie</li></country></list><tree><noCountry><name sortKey="Casley Smith, J" sort="Casley Smith, J" uniqKey="Casley Smith J" first="J" last="Casley-Smith">J. Casley-Smith</name><name sortKey="Jamal, S" sort="Jamal, S" uniqKey="Jamal S" first="S" last="Jamal">S. Jamal</name></noCountry><country name="Australie"><noRegion><name sortKey="Casley Smith, J R" sort="Casley Smith, J R" uniqKey="Casley Smith J" first="J R" last="Casley-Smith">J R Casley-Smith</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 00B479 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 00B479 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:8257235
|texte= Reduction of filaritic lymphoedema and elephantiasis by 5,6 benzo-alpha-pyrone (coumarin), and the effects of diethylcarbamazine (DEC).
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:8257235" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |